UNSPSC 51112015: Imatinib mesiate or mesylate

This classification denotes a tyrosine kinase inhibitor with the molecular formula C29H31N7O.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8A1O1M485B, chemically known as benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)aminophenyl)-, methanesulfonate salt, but more generally known as imatinib mesylate, which bears US NIH Compound Identifier 5291.

UNSPSC 51112015 Imatinib mesiate or mesylate is a Commodity code under which state and local governments procure branded and generic pharmaceutical products, including disease-specific therapies and over-the-counter medications, through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and facilities. The code appears in multistate agreements that establish standing contracts with manufacturers and wholesalers to supply defined pharmaceutical inventories at negotiated pricing, with vendors required to maintain compliance certifications in current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), demonstrate capacity to fulfill orders through authorized pharmaceutical wholesalers, and offer flexible pricing models such as flat-fee, net-price, or WAC-minus structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities in Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), submit comprehensive product information including National Drug Codes and packaging configurations, maintain contractual relationships with at least two of the three wholesalers with chargeback systems, and carry insurance including $5 million commercial general liability and $2 million network security and privacy liability. The contract term is two years for new responders with optional extensions, effective July 1, 2026, contingent on product availability by May 15, 2026. Evaluation is weighted toward price competitiveness (75 percent), with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Proposals were due March 26, 2026.